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Here, we targeted exon 2 of TLE1 using CRISPR-Cas9 based genome
engineering (Ran et al. 2013) to generate a TLE1 homozygous knockout
hESC line, TLE1-464-G04. This approach generated a 1 bp biallelic inser-
tion in exon 2 of TLE1 (Fig. 1A). This insertion was predicted to shift the
TLE1 full-length reading frame, resulting in loss of TLE1 expression. To
this end, the hESC line WA01 was transfected with constructs express-
ing Cas9 nuclease coupled with puromycin resistance and an sgRNAtt).
. This is an open access article undertargeting exon 2 of TLE1. Cells were then selected with puromycin and
plated at clonal density to allow for targeted colonies to emerge. We
manually isolated a total of 94 individual colonies, which were expand-
ed in 96-well plates and then duplicated for cell freezing and extraction
of genomic DNA. To detect the presence of frame-shift mutations, the
region ﬂanking the predicted cut site of exon 2 was PCR ampliﬁed,
barcoded and deep-sequenced. The putative TLE1 homozygous clone,
TLE1-464-G04 (TLE1−/−), and a paired wild-type TLE1 clone, TLE1-
464-A01 (TLE1+/+), were expanded and banked for further analyses.
Western blot analysis revealed undetectable levels of full-length
TLE1 protein in TLE1−/− cells relative to TLE1+/+ cells (Fig. 1B). These
results are consistent with the 1 bp insertion in exon 2 leading to dis-
ruption of TLE1 expression. Genomic integrity of TLE1+/+ and TLE1−/−
cell lines was conﬁrmed by G-banded karyotype analysis (Fig. 1C).
Stem cell colonies grown from both cell lines continued to express the
pluripotency markers OCT4, SOX2, SSEA-4, and TRA-1-60 (Fig. 1D)
and maintained three germ layer differentiation capacity, as evidenced
by expression of AFP (endoderm), SMA (mesoderm) and β-III Tubulin
(ectoderm) following in vitro embryoid body differentiation (Fig. 1E).
Taken together, the TLE1 homozygous knockout hESC line described
here is karyotypically normal and retains pluripotency characteristics. It
has potential to gain insight into how TLE1 functions in both normal de-
velopment and disease.Materials and methods
Cell culture
The XY hESC line WA01 was obtained fromWiCell (Thomson et al.
1998) (www.wicell.org). Cells were grown in mTeSR1 medium (Stem
Cell Technologies 05850) on plates pre-coated with Geltrex (Life Tech-
nologies A1413301) and maintained under standard conditionsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Generation of the TLE1 homozygous knockout hESC line TLE1-464-G04 by CRISPR-Cas9 editing. (A) Cas9 nuclease approach to create a 1 bp insertion in exon 2 of TLE1. Grey box
denotes the sgRNA target site and arrows show the location of Cas9 cleavage. (B) Western blot analysis reveals non-detectable (n.d.) levels of TLE1 protein in TLE1-464-G04 (TLE1−/−)
cells relative to TLE1-464-A01 (TLE1+/+) cells. Relative expression of TLE1 protein was quantiﬁed by calculating pixel density of TLE1 signal relative to GAPDH signal from the blot.
Errors bars represent standard error of the TLE1/GAPDH ratios from the two independent TLE1+/+ sample lysates. (C) Chromosome analyses of TLE1+/+ and TLE1−/− lines show a
normal karyotype (46, XY). (D) Immunostaining of TLE1+/+ and TLE1−/− cells with pluripotency markers OCT4, SOX2, SSEA-4, and TRA-1-60. (E) Immunostaining of embryoid bodies
derived from TLE1+/+ and TLE1−/− cells reveals differentiation to all three germ layers: AFP, endoderm; SMA, mesoderm; β-III Tubulin, ectoderm.
431A. Herring et al. / Stem Cell Research 17 (2016) 430–432(37 °C, 5% CO2). Cells were passaged using 1mMEDTA (Fluka 03690) in
PBS or TrypLE Express (Life Technologies 12604021).
CRISPR guide selection and cloning
A CRISPR guide targeting exon 2 of TLE1was designed using http://
crispr.mit.edu. Oligonucleotides (IDT) corresponding to the sgRNA
(TAATCCGGTCCAGGGACTCC) were cloned into a pU6-sgRNA vector (a
gift from Feng Zhang, Broad Institute) to generate the guide plasmid.
Gene targeting and clonal selection
For electroporation, hESCs were pre-incubated with “1:1 medium”
composed of a 1:1 mixture of mTeSR1 medium and “hESC medium”
[hESC medium: KO DMEM (Gibco 10829-018) with 20% KOSR (Gibco
10828-028), 1% Glutamax (Gibco 35050-061), 1% MEM NEAA (Corning
25-025-Cl), 0.1% 2-mercaptoethanol (Gibco 21985-023) and 20 ng/ml
bFGF (EMDMillipore GF003AF)] supplementedwith 10 μMROCK inhib-
itor (Υ-27632). For electroporation, 2.5 × 106 cells were re-suspended
in R Buffer, mixed with DNA and electroporated at 1050 V, 30 ms, 2
pulses using 100 μl tips (NEON, Life Technologies MPK10096) with
1.4 μg guide plasmid and 7 μg Cas9 nuclease-puromycin plasmid
pX459 (Addgene Plasmid # 48139).
Following electroporation, cells were dispensed into 10 cm Geltrex
coated plates in 1:1 medium plus ROCK inhibitor. After 24 h, cells
were treated with 1 μM puromycin (Sigma Aldrich P8833) for 24 h.Cells were then maintained in 1:1 medium for 10 days to allow for
colony formation.
A total of 94 individual hESC colonies were manually picked and
seeded into Geltrex-coated 96-well plates in 1:1 medium plus ROCK
inhibitor. Colonies were allowed to expand for 10 days and clones in
96-well plates were then duplicated for cell freezing and genomic
DNA extraction. Clones were frozen in 96-well plates using 50% 1:1me-
diumwith ROCK inhibitor, 40% FBS (VWR SH30070.03) and 10% DMSO
(Sigma D2650). Genomic DNA was extracted overnight at 55 °C in
DirectPCR Lysis Reagent (Viagen 102-T) with Proteinase K (Roche
03115828001) followed by a 1 h 90 °C incubation.
Screening and sequence analysis
Primers containing Illuminamultiplexing adapters (Ilumina) and spe-
ciﬁc to exon 2 of TLE1 (F: ACACTCTTTCCCTACACGACGCTCTTCCGATCT
GACGCCCGCGACCAC and R: GTGACTGGAGTTCAGACGTGTGCTCTT
CCGATCTCCCAGACGCCGCACC, underlined = adaptor sequence) were
used to PCR amplify a 146 bp TLE1 sequencing amplicon with Q5 Hot
Start High-Fidelity Master Mix (NEB M04945). A second round of PCR
ampliﬁcation was performed on the 146 bp TLE1 amplicon used to in-
corporate well-speciﬁc barcode IDs (Broad Institute). Barcoded PCR
products were pooled and gel-puriﬁed (Zymo Research D4008), run
on a 2100 BioAnalyzer (Agilent Technologies) for quality assessment
and submitted forMiSeq paired-end deep sequencing (Broad Institute).
Sequencing results were analysed using the OutKnocker indel-calling
program (www.OutKnocker.org) (Schmid-Burgk et al. 2014).
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Embryoid bodies (EBs) were generated as described (Klim et al.
2010). Brieﬂy, hESCs were grown in ultra low-attachment ﬂasks in “EB
medium” [composed of IMDM (Life Technologies 12440079), 15% FBS,
1% NEAA and 0.1 mM 2-mercaptoethanol] for 2.5 weeks. EBs were
then seeded into Geltrex-coated 12-well plates and allowed to differen-
tiate under adherent conditions in EB medium for one additional week
prior to ﬁxation and immunostaining. For neuron generation, EBs were
treated with dual SMAD inhibition (10 μM SB431542 and 100 nM
LDN193189).
Western blot analysis
Two independently grown replicates of TLE1-464-G04 and TLE1-
464-A01 were lysed using Pierce IP lysis buffer (Life Technologies
87787) with protease inhibitors (Sigma Aldrich 11836153001). 20 μg
protein as determined by Pierce BCA Protein Assay kit (Thermo Scientif-
ic 23227) was loaded onto Bolt 4–12% Bis-Tris Plus gels (Invitrogen).
Gels were dry blotted to nitrocellulose membranes (iBlot 2 NC
Ministacks, Invitrogen) by the iBlot 2 transfer system (Invitrogen). The
following antibodies were used: TLE1 (Abcam ab183742; 1:2000),
GAPDH (EMD MAB374; 1:2000), α-rabbit HRP-linked F(ab’)2 (GE Life
Sciences NA9340; 1:5000) and α-mouse HRP-linked F(ab’)2 (GE Life
SciencesNA9310; 1:5000). Blotswere visualized on a ChemiDocMP Im-
aging System (BioRad) using a SuperSignal West Femto kit (Pierce).
Pixel density quantiﬁcation of TLE1 and GAPDH was performed with
ImageJ software (https://imagej.nih.gov/ij/).
Immunostaining
hESC colonies and EBs were ﬁxed with 4% paraformaldehyde in PBS
for 15 min at room temperature, blocked and permeabilized with 0.1%
TritonX-100 and 4% serum in PBS for 1 h and incubated with the appro-
priate primary antibody. Following primary antibody incubation, cellswere washed with PBS and incubated with the appropriate secondary
antibody (Alexa Fluor 488 or 594, 1:500, Invitrogen) for 1 h. Cells
were then washed with PBS and incubated with DAPI before imaging
at 20× magniﬁcation. The following primary antibodies were used:
OCT4 (R&D Systems AF1759; 1:250), SSEA-4 (SCBT SC21704; 1:250),
TRA-1-60 (SCBT SC21705; 1:200), SOX2 (R&D Systems MAB2018;
1:200), AFP (Sigma A8452; 1:250), SMA (Sigma A2547; 1:2000), β-III
Tubulin (R&D Systems MAB1195; 1:3000).
Analysis of genomic integrity
Cytogenetic analysis was performed by Cell Line Genetics (www.
clgenetics.com) on twenty G-banded metaphase cells from each cell
line.
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